Pliant Therapeutics Files 8-K
Ticker: PLRX · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
Pliant Therapeutics filed an 8-K, standard reporting, no new info.
AI Summary
Pliant Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting other events and financial statements/exhibits as of February 7, 2025. The filing does not disclose specific material events or financial details beyond the reporting dates and standard corporate information.
Why It Matters
This 8-K filing indicates Pliant Therapeutics has submitted required corporate and financial reporting documents to the SEC. It does not contain new operational or financial information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for reporting purposes and does not contain any new material information that would suggest increased risk.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- February 7, 2025 (date) — Earliest event reported
- February 10, 2025 (date) — Date of report
- 331 Oyster Point Blvd (location) — Principal Executive Offices
- South San Francisco, CA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Pliant Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 7, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on February 10, 2025.
What is the principal executive office address for Pliant Therapeutics, Inc.?
The principal executive office address for Pliant Therapeutics, Inc. is 331 Oyster Point Blvd, South San Francisco, CA 94080.
Does this filing disclose any specific new material events or financial results?
No, this filing is a routine report and does not disclose specific new material events or financial results beyond the reporting dates.
What is the SIC code for Pliant Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Pliant Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-02-10 07:01:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Mar
Filing Documents
- d931376d8k.htm (8-K) — 25KB
- d931376dex991.htm (EX-99.1) — 8KB
- g931376g0208072810828.jpg (GRAPHIC) — 2KB
- 0001193125-25-023130.txt ( ) — 155KB
- plrx-20250207.xsd (EX-101.SCH) — 3KB
- plrx-20250207_lab.xml (EX-101.LAB) — 17KB
- plrx-20250207_pre.xml (EX-101.PRE) — 11KB
- d931376d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 7, 2025, titled "Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: February 10, 2025 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer